Development and Commercialization of Biosimilars in India - The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations th

ADVERTISEMENT

Development and Commercialization of Biosimilars in India
The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations that may alleviate these challenges.


BioPharm International
Volume 24, Issue 11, pp. 36-40

REFERENCES

1. G. Walsh, Nature Biotechnol. 28 (9) 917–924 (2010).

2. J. Hodgson, Nature Biotechnol. 27 (11) 963–965 (2009).

3. P. Narang, Datamonior Biosimilar Series 2008 (Datamonitor, London. June 2009).

4. C. Chakraborty and G. Agoramoorthy, Biotechnology Advances 28 (1) 1–6 (2010).

5. S. Chaturvedi, The Indian Jrnl. of Labour Econ. 52 (2) 693–712 (2009).

6. S. Natesh and M. Bhan, Current Sci. 97, 157–169 (2009).

7. C.J. Mathew, Business Standard (Oct. 2007), p. 16.

8. K. Jayaraman, Nature Biotechnol. 28 (9) 883–884 (2010).

9. E.S. Langer, Gen. Engin. & Biotechnol. News 30 (5) 2010

10. A.S. Rathore, Trends in Biotechnol, 27, (12) 698–705 (2009).

11. A.S. Rathore and I.S. Krull, LCGC North America 28, 598–600 (2010).

12. J.F. Tremblay, Chemical & Engin. News (Aug. 2010), p. 23.

13. A. S. Rathore and H. Winkle H, Nature Biotechnol. 27 (1) (2009) 26–34 (2009).

14. A.S. Rathore, Trends in Biotechnology, 27 (9), 546–553 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here